Becton Dickinson and Co Stock Forecast for 2023 - 2025 - 2030
Updated on 04/18/2024
Becton Dickinson and Co Stock Forecast and Price Target
Given the average yearlong price target of $280.00 provided by eight prominent analysts over the past few months, there is a potential upside of approximately 20.09% from the last closing price in April, 2024 for Becton Dickinson and Co's stock if it is reached. This estimation is based on a high estimate of $325.00 and a low estimate of $240.00. If you're interested in BDX stock, looking at its competitors might also be a good idea.
20.09% Upside
Becton Dickinson and Co Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Becton Dickinson and Co's Price has decreased by 100.00%, from $212.16 to $0.00. For next year, analysts predict Fair Value of $289.54, which would mean an increase of 100.00%. Over the next seven years, experts predict that Becton Dickinson and Co's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STE Stock Forecast | STERIS | Outperform |
13
|
$200.81 | Buy/Sell | $238.33 | 18.52% |
| ABMD Stock Forecast | Abiomed | - |
16
|
$377.79 | Buy/Sell | $380.00 | -88.33% |
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$207.38 | Buy/Sell | $263.46 | 27.78% |
| PEN Stock Forecast | Penumbra | Outperform |
9
|
$201.84 | Buy/Sell | $258.62 | 42.22% |
| GMED Stock Forecast | Globus Medical | Outperform |
16
|
$50.75 | Buy/Sell | $64.58 | 18.23% |
Becton Dickinson and Co Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Becton Dickinson and Co's Revenue has grown by 13.17%, rising from $17.12B to $19.37B. For next year, analysts predict Revenue of $20.49B, which would mean an increase of 5.79%. Over the next seven years, experts predict that Becton Dickinson and Co's Revenue will grow at a rate of 14.91%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMSI Stock Forecast | Merit Medical Systems | Outperform |
14
|
$70.99 | Buy/Sell | $89.25 | 24.67% |
| GKOS Stock Forecast | Glaukos | Outperform |
7
|
$95.13 | Buy/Sell | $87.33 | 13.00% |
| HAE Stock Forecast | Haemonetics | Outperform |
16
|
$83.46 | Buy/Sell | $70.17 | 31.80% |
.jpg)
Becton Dickinson and Co Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Becton Dickinson and Co's Dividend per Share has grown, rising from $3.16 to $3.64 – a growth of 15.19%. In the next year, analysts believe that Dividend per Share will reach $4.94 – an increase of 35.71%. For the next seven years, the forecast is for Dividend per Share to grow by 23.08%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NARI Stock Forecast | Inari Medical | Outperform |
14
|
$38.64 | Buy/Sell | $82.67 | 81.16% |
| ICUI Stock Forecast | ICU Medical | Outperform |
16
|
$96.90 | Buy/Sell | $153.50 | 40.87% |
| NUVA Stock Forecast | NuVasive | - |
14
|
$4.86 | Buy/Sell | $73.81 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATRC Stock Forecast | AtriCure | Outperform |
8
|
$23.39 | Buy/Sell | $55.00 | 145.83% |
| LMAT Stock Forecast | LeMaitre Vascular | Outperform |
18
|
$62.62 | Buy/Sell | $59.86 | 11.79% |
| IRMD Stock Forecast | IRadimed | Buy |
16
|
$40.36 | Buy/Sell | $60.00 | 48.66% |
Becton Dickinson and Co EBITDA Forecast for 2023 - 2025 - 2030
Becton Dickinson and Co's EBITDA has seen impressive growth In the last three years, rising from $4.67B to $5.04B – a growth of 7.81%. In the next year, analysts believe that EBITDA will reach $5.98B – an increase of 18.63%. For the next seven years, the forecast is for EBITDA to grow by 51.64%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LUNG Stock Forecast | Pulmonx | Outperform |
4
|
$7.50 | Buy/Sell | $15.33 | 126.67% |
| ATRI Stock Forecast | Atrion | - |
18
|
$352.20 | Buy/Sell | $946.00 | -100.00% |
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$13.02 | Buy/Sell | $18.00 | 15.21% |
Becton Dickinson and Co EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Becton Dickinson and Co's EBIT has grown by 9.17%, rising from $2.52B to $2.75B. For the next year, analysts predict that EBIT will reach $4.88B – an increase of 77.26%. Over the next seven years, experts believe that Becton Dickinson and Co's EBIT will grow at a rate of 127.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MON Stock Forecast | Misonix | - |
7
|
$26.54 | Buy/Sell | $28.00 | -100.00% |
| LYRA Stock Forecast | Lyra Therapeutics | Buy |
4
|
$5.39 | Buy/Sell | $11.80 | 122.63% |
| ANGO Stock Forecast | AngioDynamics | Buy |
8
|
$6.12 | Buy/Sell | $16.33 | 112.42% |
Becton Dickinson and Co EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Becton Dickinson and Co's EPS has decreased by 100.00%, from $10.20 to $0.00. For next year, analysts predict EPS of $13.92, which would mean an increase of 100.00%. Over the next seven years, experts predict that Becton Dickinson and Co's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| APEN Stock Forecast | Apollo Endosurgery | - |
10
|
$10.00 | Buy/Sell | $0.00 | -100.00% |
| SGHT Stock Forecast | Sight Sciences | Hold |
5
|
$5.24 | Buy/Sell | $3.88 | 0.19% |
| TELA Stock Forecast | TELA Bio | Buy |
6
|
$5.15 | Buy/Sell | $15.20 | 171.84% |
Site Navigation
.jpg)